Modality
Cell Therapy
MOA
KRASG12Ci
Target
PD-L1
Pathway
Cell Cycle
DLBCL
Development Pipeline
Preclinical
Oct 2017
→ Dec 2028
PreclinicalCurrent
NCT08545208
1,498 pts·DLBCL
2025-01→2028-04·Recruiting
NCT03863577
1,835 pts·DLBCL
2017-10→2028-12·Not yet recruiting
3,333 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-04-162.0y awayInterim· DLBCL
2028-12-192.7y awayInterim· DLBCL
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Not yet…
Preclinical
Recruit…
Catalysts
Interim
2028-04-16 · 2.0y away
DLBCL
Interim
2028-12-19 · 2.7y away
DLBCL
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08545208 | Preclinical | DLBCL | Recruiting | 1498 | Mayo |
| NCT03863577 | Preclinical | DLBCL | Not yet recr... | 1835 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ |